Get the Daily Brief
Latest Biotech News
Late-stage bone drug fails: Ultragenyx, Mereo see stocks tumble
Ultragenyx Pharmaceutical and partner Mereo BioPharma announced the categorical failure of their late-stage candidate for a rare bone disease in a pivotal trial. The companies disclosed the...
Genmab pulls plug on lung bispecific... BioNTech had already walked
Genmab announced it will terminate clinical development of acasunlimab, a bispecific antibody previously co-developed with BioNTech. The decision follows BioNTech’s exit from the asset last year...
FDA clears Diasorin molecular POC: Four‑plex test wins 510(k) and CLIA waiver
The US Food and Drug Administration granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes platform and its four-plex molecular assay for Flu A/B, RSV and SARS‑CoV‑2. Diasorin said...
Harbour Biomed inks radionuclide conjugate pact with Lannacheng
Harbour Biomed and Yantai Lannacheng Biotechnology signed a long-term strategic collaboration to advance next-generation radionuclide–drug conjugates (RDCs) for cancer treatment. The partners will...
Adlai Nortye licenses pan‑RAS oral AN‑9025 to Ask Pharm
Adlai Nortye Ltd. granted an exclusive license to Jiangsu Aosaikang Pharmaceutical (Ask Pharm) for AN‑9025, an oral pan‑RAS(ON) inhibitor designed to target a broad spectrum of activating RAS...
First‑in‑class GAS41 YEATS inhibitor unveiled for NSCLC
Researchers disclosed a first‑in‑class inhibitor targeting GAS41, the YEATS4‑encoded chromatin reader frequently overexpressed in non‑small‑cell lung cancer (NSCLC). Preclinical data presented...
New BTK inhibitors curb GBM invasion – selectivity solves ibrutinib's limits
Researchers reported novel Bruton tyrosine kinase (BTK) inhibitors that block invasion and progression in glioblastoma (GBM) models while offering improved selectivity relative to ibrutinib. The...
Plasma protein profile flags cancer in symptomatic patients
A recent study unveiled a plasma protein profiling approach capable of predicting cancer in patients presenting with non‑specific symptoms. The minimally invasive test integrates multiplexed...
Potent cross‑neutralizing antibodies neutralize Marburg and Ravn viruses
Scientists discovered a class of potent antibodies that cross‑neutralize Marburg virus and the related Ravn virus, according to a report in npj Viruses. The antibodies show broad neutralizing...
PCMT1 linked to new degron pathway on cereblon substrates
Biochemists reported that protein carboxymethyltransferase 1 (PCMT1) generates a C‑terminal degron on substrates of cereblon (CRBN), the E3 ligase adapter central to the activity of...
Diasorin wins FDA OK: 15‑minute molecular POC cleared
The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s LIAISON Nes four‑plex molecular assay, enabling detection of influenza A/B, RSV and SARS‑CoV‑2 at the...
Plasma protein panel spots cancer in symptomatic patients
Researchers published a plasma protein profiling study showing a blood‑based panel can predict cancer in patients presenting with non‑specific symptoms. The lead finding: a multiplex protein...
Meta‑analysis: CAR‑T and bispecifics split outcomes in indolent B‑cell NHL
A new meta‑analysis compared chimeric antigen receptor T‑cell (CAR‑T) therapy with bispecific antibody treatments for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas. The pooled...
Researchers find cross‑neutralizing antibodies vs Marburg and Ravn
Scientists reported discovery of potent cross‑neutralizing human antibodies that neutralize Marburg virus and the related Ravn virus, according to a paper in npj Viruses. The antibodies target...
Senhwa pushes CX‑5461 into combo play with ADC and PD‑1 tie‑up
Senhwa Biosciences announced a clinical collaboration with BeOne Medicines to evaluate CX‑5461 in combination with an antibody‑drug conjugate (ADC) and BeOne’s marketed PD‑1 inhibitor, targeting...
Genetic screening in oncology... adoption lags despite safety gains
A MedCity News report reviewed emerging genetic screening tools that predict rare but deadly adverse reactions to common cancer drugs and improve drug selection. Despite mounting evidence of...
Antibiotic pollution accelerates resistance in Indian sewage: Nature Commun.
A Nature Communications study linked widespread antibiotic contamination in urban Indian sewage with accelerated selection for antimicrobial‑resistant bacteria and resistance genes. Researchers...
AI in biotech... roadmap to drug discovery and personalized care by 2033
An industry analysis published by BioTecNika projects that artificial intelligence will transform drug discovery pipelines and personalized medicine by 2033. The report synthesizes case studies...
Mitochondrial gene therapy: progress reported, obstacles remain
A field review assessed progress and outstanding challenges for mitochondrial gene therapy, detailing advances in delivery vectors, allotopic expression and mtDNA editing techniques. Researchers...
Vaccine targets immune evasion in EBV‑linked nasopharyngeal carcinoma
A study led by Gan et al. reported a therapeutic vaccine designed to counter immune‑evasive mechanisms in Epstein‑Barr virus (EBV)‑associated nasopharyngeal carcinoma (NPC). The vaccine stimulates...